BIRMINGHAM Ala. Aug 16 2010 BUSINESS WIRE BioCryst Pharmaceuticals Inc. NASDAQ BCRX today announced that its partner Green Cross Corporation has received marketing and manufacturing approval from KFDA Korean Food Drug Administration for intravenous i.v. peramivir to treat patients with influenza A B viruses including pandemic
Dec 11 2017 Oasmia Pharmaceutical AB NASDAQ OASM a developer of a new generation of drugs within human and veterinary oncology announced today that it has received marketing approval for Paclical in Kazakhstan. Paclical is the first water soluble cancer drug with paclitaxel to receive a market authorization.
In September 2017 Kyorin submitted a marketing application for vibegron to the Japan Pharmaceuticals and Medical Devices Agency and received marketing approval from Japan’s Ministry of Health Labour and Welfare for vibegron for the treatment of adults with OAB in September 2018.
Aug 20 2021 Micurx Pharmaceuticals Inc. has won marketing approval from China s NMPA for its lead antibacterial contezolid for treating adults with complicated skin and soft tissue infection.2nd June 2021. Kyorin Pharmaceutical Receives Marketing Approval for Oral Quinolone Antibacterial Agent Lasvic Tablets 75mg 20th September 2019. Company Profiles
Dec 01 2014 flutiform has also been launched by Mundipharma in Australia Hong Kong Israel Singapore and South Korea and by Kyorin Pharmaceutical Co Ltd Kyorin in Japan. In Italy Abriff has been launched by Mundipharma’s co marketing partner Zambon Italia srl.
Jan 22 2021 Kyorin Pharmaceutical Receives Marketing Approval for the Interstitial cystitis Zymso Intravesical Solution 50 November 27 2020 Kyorin Pharmaceutical Receives Marketing Approval for injectable New Quinolone Antibacterial Agent Lasvic Intravenous Drip Infusion Kit 150mg October 12 2020
Dec 29 2021 Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin. December 29 2021 11 24 AM Eastern Standard Time. WOODCLIFF LAKE N.J.
in concert with respect to collaborating in the development marketing sale and obtaining regulatory approval of generic copies of branded pharmaceutical products including 0.5 w/v gatifloxacin ophthalmic solutions. Jurisdiction and Venue 19. Paragraphs 1 18 are incorporated herein as set forth above. 20.
Endra Life Sciences is switching its FDA application for its Thermo Acoustic Enhanced UltraSound TAEUS from the 510 k marketing clearance pathway and is now seeking a de novo approval. The company had submitted a 510 k application for the TAEUS System which is intended to characterize fatty liver tissue to noninvasively monitor nonalcoholic fatty liver
Nov 08 2018 Under an agreement announced in March 2016 Kyorin Pharmaceutical granted Kissei Pharmaceutical co development and co marketing rights for vibegron in Japan. Both companies would shoulder the development costs and following receipt of marketing approval by Kyorin the companies will jointly market the product .
Sep 15 2020 aTyr Pharma Announces Partner Kyorin Pharmaceutical Co. Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in Japan
In January 2020 we entered into a license with Kyorin Pharmaceutical Co. Ltd. Kyorin for the development and commercialization of ATYR1923 for ILDs in Japan. Under the collaboration and license agreement with Kyorin the Kyorin Agreement Kyorin received an exclusive right to develop and commercialize ATYR1923 in Japan for all forms of ILDs.
Aug 06 2020 Catalyst Pharmaceuticals’ Firdapse amifampridine phosphate Receives Marketing Approval in Canada for Patients with LEMS August 06 2020 08 03 ET Source Catalyst Pharmaceuticals Inc.
Oct 12 2020 KYORIN Pharmaceutical Co. Ltd. KYORIN Pharmaceutical uses a franchise customer strategy where its marketing efforts are focused on respiratory otolaryngology and urology indications. In drug
Sep 20 2019 Kyorin Pharmaceutical Receives Marketing Approval for Oral Quinolone Antibacterial Agent Lasvic Tablets 75mg September 20 2019. Kyorin Pharmaceutical Receives Marketing Approval for Oral Quinolone Antibacterial Agent Lasvic Tablets 75mg PDF 123.8 KB
Nov 27 2020 Kyorin Pharmaceutical Receives Marketing Approval for injectable New Quinolone Antibacterial Agent Lasvic Intravenous Drip Infusion Kit 150mg PDF 103.8 KB Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.
Dec 29 2021 Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin. Eagle Pharmaceuticals Inc. Nasdaq EGRX Eagle or the Company today announced
AbbVie GK Alfresa Pharma Asahi Kasei Medical EA Pharma Co Ltd Kyorin Pharmaceutical Co Ltd Mochida Pharmaceutical Nippon Kyaku Otsuka Holdings Co Ltd Thermo Fisher Scientific and ZERIA and funding from Pfizer Inc to attend study related meetings.
Dec 29 2021 Eagle Pharmaceuticals Inc. Nasdaq EGRX Eagle or the Company today announced that the U.S. Food and Drug Administration has determined that the Company has maintained its 180 days of marketing exclusivity for its recently approved abbreviated new drug application ANDA for vasopressin. In August the U.S. District Court for the District of
Aug 10 2021 GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome LGS or Dravet syndrome in conjunction with clobazam for patients two years of age and older. GW also received positive recommendation from the UK s National Institute for Health and
Jan 06 2020 Shares of aTyr Pharma Inc. LIFE soared more than 40 on Monday after the Company announced a collaboration and license agreement with Kyorin Pharmaceutical Co. Ltd. for the development and
BEIJING CAMBRIDGE Mass. BUSINESS WIRE CANbridge Pharmaceuticals Inc. a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers announced that it received marketing approval from China’s National Medical Products Administration NMPA for Hunterase Idursulfase beta Injection an enzyme replacement
Lascufloxacin. Lascufloxacin trade name Lasvic is an fluoroquinolone antibiotic drug for the treatment of bacterial infections. It has been approved since 2019 in Japan to treat community acquired pneumonia otorhinolaryngological infections and respiratory tract infections. It has activity against various Gram positive bacteria including
According to the suit Allergan which obtained licensing rights from Kyorin and Senju in 2000 for U.S. sales of the treatment stopped marketing and promoting Zymar to physicians in order to
Nov 12 2020 In 2017 Urovant has licensed the vibegron global rights except Japan and some Asian regions. After Merck Kyorin Pharmaceuticals and Kissei Pharmaceuticals reached an agreement the product was launched in Japan in 2018 under the brand name Beova. In December 2019 Urovant submitted an NDA for vibegron at a dose of 75 mg once a day to the
This report includes KYORIN Co. Ltd. s contact information and business summary tables graphs a list of partners and targets a breakdown of financial and legal advisors deal types top deals by deal value detailed deal reports and descriptions and contact details of the partner target investor and vendor firms where disclosed.
BQ+ Medical not only produce components for manufacturers all over the world, but also provide private label manufacturing for leading brand distributors in different countries.
No.18,Cheye Road,Songjiang District,Shanghai 201611 China.
Tel: 86-021-57743953
Email: [email protected]
Copyright © BQ PLUS MEDICAL CO., LTDSitemap | Contact Us |
